TAVR for Severe Aortic Regurgitation
Guideline Position on TAVR for Aortic Regurgitation
- The American College of Cardiology, American Association for Thoracic Surgery, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons expert consensus explicitly excludes severe aortic regurgitation from current TAVR indications, regardless of the patient's surgical risk profile, due to insufficient evidence to establish a favorable risk-benefit ratio 1, 2
- The exclusion of severe aortic regurgitation from TAVR indications is based on the absence of adequate clinical trial data, not proven harm, and applies to patients with prohibitive, high, intermediate, or low surgical risk 1, 2
Clinical Evidence and Device Design
- TAVR devices were designed and tested for calcified, stenotic aortic valves, where calcification provides structural support for valve anchoring, and the rigid annulus prevents valve migration 1, 2
- Severe aortic regurgitation presents fundamentally different anatomic and hemodynamic challenges, including lack of calcification, dilated annulus, and the need for complete seal rather than gradient reduction 1, 2
Current Evidence Base and Recommended Management
- The PARTNER trial showed TAVR reduced mortality compared to medical therapy in prohibitive-risk aortic stenosis patients, but this evidence cannot be extrapolated to aortic regurgitation 3, 4, 5
- Surgical aortic valve replacement remains the standard of care for patients with severe symptomatic aortic regurgitation who are acceptable surgical candidates 1, 2
- For prohibitive surgical risk patients with severe aortic regurgitation, medical management with afterload reduction is the current standard, and consideration of enrollment in clinical trials investigating AR-specific transcatheter devices may be appropriate 1, 2